chlorhexidine has been researched along with fasudil in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
Fujimura, K; Hara, Y; Hasegawa, K; Hayashi, K; Homma, K; Hosoya, K; Itoh, H; Minakuchi, H; Tokuyama, H; Tonozuka, Y; Wakino, S; Washida, N | 1 |
2 other study(ies) available for chlorhexidine and fasudil
Article | Year |
---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Rho-kinase inhibition ameliorates peritoneal fibrosis and angiogenesis in a rat model of peritoneal sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Animals; Anti-Infective Agents, Local; Cells, Cultured; Chlorhexidine; Disease Models, Animal; Enzyme Inhibitors; Epithelium; Humans; Immunoenzyme Techniques; Male; Neovascularization, Pathologic; Peritoneal Fibrosis; Pleural Cavity; Pyridines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; rho-Associated Kinases; RNA, Messenger; Transforming Growth Factor beta1; Vascular Endothelial Growth Factor A | 2011 |